A high tumor mutation burden (TMB) is associated with the accumulation of neoantigen-specific CD8+ TILs and better ICI responsiveness (Li et al., 2021; Fehlings et al., 2017; Gubin et al., 2014; Palmeri et al., 2022; Cristescu et al., 2022). Here, CD8A is linked to neoplasm.